Palatin Technologies, Inc. (AMEX: PTN), a biopharmaceutical company, has dedicated their efforts to developing peptide, peptide mimetic and small molecule agonist compounds. Their primary focus is on melanocortin and natriuretic peptide receptor systems, including acute hospital care products in the cardiovascular field, for treating congestive heart failure, hard-to-control hypertension as well as cardiac surgery organ protection. For further information, visit the Company’s web site at www.palatin.com.
- 17 years ago
QualityStocks
Palatin Technologies, Inc. (AMEX: PTN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology,…
-
QualityStocksNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Stands Distinct Against Walker Lane Backdrop
Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is positioned as investors view the Walker Lane corridor in…
-
QualityStocksNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Targets $1 Billion AUM for Tokenized USD Money Market Product by Year-End 2025
Solowin (NASDAQ: SWIN), a financial services firm bridging traditional and digital assets, announced an initiative…